Nat Brinn has a successful track record of venture capital and other private investments, acquisitions and business management. He is a partner of both Vital Venture Capital and VC23. Nat has invested in 25 early-stage biotechnology and software companies including Gingko Bioworks, Quantalife (acquired by Bio-Rad), Twist Bioscience (now public through an IPO), 10X Genomics (now public through an IPO), AxioMx (acquired by Abcam), HealthTell (acquired by iCarbonX), CD Diagnostics (acquired by Zimmer), General Automation Lab Technologies, Tangen Biosciences and Talee Bio (acquired by Roivant). Nat has served as a director of various portfolio companies. The Vital and VC23 overall venture portfolio returns have been in excess of 5x invested capital thus far.
His previous experience includes roles at HSA Bank (CEO), Webster Bank (EVP) and other firms in corporate development and investment positions.
He has an MBA in finance and accounting from Duke University, where he was a Fuqua Scholar and class graduation speaker. Nat did his undergraduate work in economics and mathematics at University of Delaware in the honors program.
Nat is attending / has attended:
The 2015 New England Venture Summit
The 2014 New England Venture Summit
The 2014 New York Venture Summit
The Life Sciences and Healthcare Venture Summit 2014
The 2013 New England Venture Summit
The 2012 New England Venture Summit
The 2019 New England Venture Summit